Patients treated with Ozempic were 24% less likely to develop kidney failure (dialysis, transplantation, or an eGFR of 50% decline), or death from kidney-related or cardiovascular causes Non-alcoholic fatty liver disease (NAFLD), aka metabolic dysfunctionassociated steatohepatitis (MASH), often goes undetected but is closely linked with obesity and metabolic dysfunction
Glucagon-Like Peptide-1 Analogues and Thyroid Cancer: An Analysis of Cases Reported in the European Pharmacovigilance Database
They work by helping the body better metabolize blood sugar and by reducing hunger and food cravings
In terms of CVD treatment, adalimumab may exhibit more significant benefits, particularly considering that psoriasis and RA themselves are cardiovascular risk factors
Microdosing GLP-1 is often discussed as a way to ease into therapy more slowly, giving the body time to adapt to appetite and gastrointestinal changes
However, if you develop eye pain, especially with redness, headache, nausea, or vision changes, seek immediate care